Literature DB >> 3198351

Gd-DOTA, a potential MRI contrast agent. Current status of physicochemical knowledge.

D Meyer1, M Schaefer, B Bonnemain.   

Abstract

The complex (Gd-DOTA) meglumine has recently been used as an MRI contrast agent in humans. Due to its particularly interesting physicochemical properties, the risk of in vivo dissociation of the complex is reduced. Indeed, as a result of the macrocyclic nature of the DOTA ligand, Gd-DOTA appears very stable, demonstrating a calculated conditional stability constant of 10(22.19) at pH = 7. Other characteristics making Gd-DOTA a positively attractive compound include slow dissociation kinetics inherent in the rigidity of the macrocycle and marked specific affinity of DOTA for gadolinium in comparison with other endogenous ions. Finally, although the relaxivity R1 of Gd-DOTA at 20 MHz appears similar to that of Gd-DTPA, Gd-DOTA demonstrates higher paramagnetic efficacy at low field strength due to greater symmetry of the complex. Such promising properties open up wide prospects for the use of Gd-DOTA in MRI.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3198351     DOI: 10.1097/00004424-198809001-00048

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  13 in total

1.  Influence of Dy3+ and Tb3+ doping on 13C dynamic nuclear polarization.

Authors:  Peter Niedbalski; Christopher Parish; Andhika Kiswandhi; Leila Fidelino; Chalermchai Khemtong; Zahra Hayati; Likai Song; André Martins; A Dean Sherry; Lloyd Lumata
Journal:  J Chem Phys       Date:  2017-01-07       Impact factor: 3.488

2.  Assessment of DCE-MRI parameters for brain tumors through implementation of physiologically-based pharmacokinetic model approaches for Gd-DOTA.

Authors:  Marios Spanakis; Eleftherios Kontopodis; Sophie Van Cauter; Vangelis Sakkalis; Kostas Marias
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-19       Impact factor: 2.745

3.  Design and assembly of supramolecular dual-modality nanoprobes.

Authors:  Shuang Liu; Pengcheng Zhang; Sangeeta Ray Banerjee; Jiadi Xu; Martin G Pomper; Honggang Cui
Journal:  Nanoscale       Date:  2015-06-07       Impact factor: 7.790

4.  Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA).

Authors:  P Brugières; A Gaston; H R Degryse; P M Parizel; A M de Schepper; I Berry; C Manelfe; F Le Bras; C Marsault; W Wichmann
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

5.  Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation.

Authors:  Björn Gustafsson; Susan Youens; Angelique Y Louie
Journal:  Bioconjug Chem       Date:  2006 Mar-Apr       Impact factor: 4.774

6.  HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation.

Authors:  Bahar Zarabi; Anjan Nan; Jiachen Zhuo; Rao Gullapalli; Hamidreza Ghandehari
Journal:  Macromol Biosci       Date:  2008-08-11       Impact factor: 4.979

Review 7.  New magnetic resonance imaging techniques for the detection of breast cancer.

Authors:  K Orang-Khadivi; B L Pierce; C M Ollom; L J Floyd; R L Siegle; R F Williams
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Synthesis and Characterization of DOTA-(amide)(4) Derivatives: Equilibrium and Kinetic Behavior of Their Lanthanide(III) Complexes.

Authors:  Azhar Pasha; Gyula Tircsó; Enikő Tircsóné Benyó; Ernő Brücher; A Dean Sherry
Journal:  Eur J Inorg Chem       Date:  2007-07-31       Impact factor: 2.524

9.  Effect of Magnetic Coupling on Water Proton Relaxivity in a Series of Transition Metal GdIII Complexes.

Authors:  Laura M Lilley; Kang Du; Matthew D Krzyaniak; Giacomo Parigi; Claudio Luchinat; T David Harris; Thomas J Meade
Journal:  Inorg Chem       Date:  2018-05-01       Impact factor: 5.165

Review 10.  Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks.

Authors:  Colin Unruh; Nicolas Van Bavel; Max Anikovskiy; Elmar J Prenner
Journal:  Molecules       Date:  2020-12-07       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.